Mirae Asset Global ETFs Holdings
CRSP icon

Mirae Asset Global ETFs Holdings’s CRISPR Therapeutics CRSP Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.7M Buy
122,658
+27,942
+30% +$1.47M 0.01% 786
2026
Q1 		$4.48M Buy
94,716
+5,008
+6% +$264K 0.01% 851
2025
Q4 		$4.71M Sell
89,708
-9,496
-10% -$569K 0.01% 819
2025
Q3 		$6.42M Sell
99,204
-6,194
-6% -$356K 0.01% 743
2025
Q2 		$5.12M Buy
105,398
+30,065
+40% +$1.16M 0.01% 751
2025
Q1 		$2.58M Sell
75,333
-4,634
-6% -$196K 0.01% 1002
2024
Q4 		$3.14M Buy
79,967
+14,125
+21% +$667K 0.01% 913
2024
Q3 		$3.1M Sell
65,842
-11,176
-15% -$567K 0.01% 930
2024
Q2 		$4.17M Buy
+77,018
New +$4.45M 0.01% 806

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CRSP Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its CRISPR Therapeutics (CRSP) stake by 30% in Q2 2026, buying an estimated $1.47M and bringing the position to 122,658 shares worth $6.7M. The position accounts for 0.01% of the portfolio, ranked #786.

Mirae Asset Global ETFs Holdings first reported a position in CRSP in Q2 2024 and has held it in 9 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 122,658 shares of CRISPR Therapeutics worth $6.7M as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 27,942 CRISPR Therapeutics shares in Q2 2026, an estimated $1.47M.
  • CRISPR Therapeutics made up 0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #786 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.